Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  primary central nervous system non-Hodgkin lymphoma
Stage/Subtype:  primary central nervous system non-Hodgkin lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 115 for your search:
Start Over
Stem Cell Transplant for Hematological Malignancy
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116428, 2012-003438-18, NCT01767467
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB-AB006, 2012-0166, NCT01854567
Rituximab&Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: OHSU-1012, 3R01CA137488, 1012, SOL-05025-L, OHSU-SOL-05025-L, NCT00293475
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0711003269, NCT00785798
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC0886, NCI-2009-00934, 08-004746, CLBH589BUS17T, P30CA015083, NCT00918333
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED10893, U1111-1116-5472, NCT01084252
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PSOC 2502, NCI-2010-00907, P30CA015704, NCT01165112
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 montha to 70
Sponsor: Other
Protocol IDs: J1055, NA_00039823, NCT01203722
Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 13 to 60
Sponsor: NCI, Other
Protocol IDs: BMT236, SU-09142011-8407, NCT01660607
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: 2013-0186, NCI-2014-01025, NCT01983969
Romidepsin + Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AAAM3752, NCT01998035
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 060051, 06-C-0051, NCT00267865
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2005LS048, UMN-0508M72589, UMN-MT2004-24, UMN-2005LS048, NCT00345865
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: H-8701-MOHEL, MOHEL, NCT00368355
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FDA IND 100712, NCT00611208
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 60
Sponsor: Other
Protocol IDs: 2008-0363, NCI-2012-01630, NCT00857389
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 75 and under
Sponsor: NCI, Other
Protocol IDs: 2212.00, NCI-2009-01244, P30CA015704, U19AI096111, P01CA018029, NCT00968630
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: L 10,321, NYMC 525, NCT01049854
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2010-0284, NCI-2012-01889, NCT01200485
The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory Central Nervous System (CNS) Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Pro00019873, NCT01235793
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2206.00, NCI-2010-02222, P30CA015704, P01CA018029, NCT01251575
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC0986, NCI-2010-02326, 10-004705, CLBH589BUS59T, NCT01261247
Start Over